Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Not Confirmed
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
27-30 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Industry Trade Show
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
27-30 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
30 Sep 2024
// James Waldron FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/cerenos-hdac-inhibitor-reduces-risks-pulmonary-arterial-hypertension-phase-2-trial
23 Sep 2022
// CISION
https://news.cision.com/cereno-scientific/r/cereno-scientific-obtains-first-patent-in-europe-for-drug-candidate-cs585,c3635866
09 Sep 2022
// CISION
https://news.cision.com/cereno-scientific/r/cereno-scientific-broadens-patent-protection-for-drug-candidate-cs585-and-strengthens-its-future-com,c3628527
Details:
CS1 is an HDAC inhibitor that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for pulmonary arterial hypertension.
Lead Product(s): Divalproex Sodium,Sodium Valproate
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: CS1
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 30, 2024
Lead Product(s) : Divalproex Sodium,Sodium Valproate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cereno's HDAC Inhibitor Reduces Risks from PAH in Phase 2 Trial
Details : CS1 is an HDAC inhibitor that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for pulmonary arterial hypertension.
Product Name : CS1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2024
Details:
Preclinical data from drug candidate CS585 demonstrating that it targets the IP receptor for prevention of thrombosis without increased risk of bleeding.
Lead Product(s): CS585
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: CS585
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: University of Michigan
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 09, 2022
Lead Product(s) : CS585
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : University of Michigan
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preclinical data from drug candidate CS585 demonstrating that it targets the IP receptor for prevention of thrombosis without increased risk of bleeding.
Product Name : CS585
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 09, 2022
Details:
CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH.
Lead Product(s): Divalproex Sodium
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: CS1
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 17, 2021
Lead Product(s) : Divalproex Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH.
Product Name : CS1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2021
ABOUT THIS PAGE